Faron Pharmaceuticals Feed

Land	Finland
Lista	First North Finland
Sektor	Hälsovård
Industri	Bioteknik

2024-08-30 08:00:14 Grant of options -2,38% | 0,57 MEUR

2024-08-30 08:00:00 Faron Pharmaceuticals Oy: Grant of options -2,38% | 0,57 MEUR

2024-08-27 08:00:12 Faron 2024 Half-Year Financial Results +24,86% | 2,57 MEUR

2024-08-27 08:00:12 FDA Grants Fast Track Designation for Bexmarilimab +24,86% | 2,57 MEUR

2024-08-27 08:00:00 Faron Pharmaceuticals Oy: Faron 2024 Half-Year Financial Results +24,86% | 2,57 MEUR

2024-08-26 08:00:00 Faron Pharmaceuticals Oy: FDA Grants Fast Track Designation for Bexmarilimab

2024-08-20 08:00:17 Notice of Half-Year Financial Results 0,00% | 0,34 MEUR

2024-08-20 08:00:00 Faron Pharmaceuticals Oy: Notice of Half-Year Financial Results 0,00% | 0,34 MEUR

2024-08-13 08:00:12 Traumakine Research Collaboration and DoD Grant +2,70% | 0,56 MEUR

2024-08-13 08:00:00 Faron Pharmaceuticals Oy: Traumakine Research Collaboration and DoD Grant +2,70% | 0,56 MEUR

2024-08-08 08:00:13 Appointment of Chief Financial Officer +9,57% | 0,80 MEUR

2024-08-08 08:00:00 Faron Pharmaceuticals Oy: Appointment of Chief Financial Officer +9,57% | 0,80 MEUR

2024-08-07 11:00:00 Grant of options -0,31% | 0,30 MEUR

2024-08-07 11:00:00 Faron Pharmaceuticals Oy: Grant of options -0,31% | 0,30 MEUR

2024-08-06 09:30:00 Faron Appoints Dr. Petri Bono as new CMO +8,33% | 0,66 MEUR

2024-08-06 09:30:00 Faron Pharmaceuticals Oy: Faron Appoints Dr. Petri Bono as new CMO +8,33% | 0,66 MEUR

2024-07-11 08:00:00 Faron Pharmaceuticals Oy: Faron Announces Positive FDA Feedback +27,78% | 2,61 MEUR

2024-06-25 15:00:00 Faron Pharmaceuticals Oy: Update on settlement +2,70% | 0,58 MEUR

2024-06-25 11:30:00 Faron Pharmaceuticals Oy: Holding(s) in Company +2,70% | 0,58 MEUR

2024-06-24 13:45:00 Faron Pharmaceuticals Oy: Holding(s) in Company -6,09% | 0,88 MEUR

2024-06-20 14:00:00 Faron Pharmaceuticals Oy: New shares registered with Finnish Trade Register +5,95% | 19,8 MEUR

2024-06-20 08:00:00 Faron Pharmaceuticals Oy: Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering +5,95% | 19,8 MEUR

2024-06-05 09:00:00 Faron Pharmaceuticals Oy: Proposed REX Retail Offer -1,90% | 1,45 MEUR

2024-06-04 08:00:00 Faron Pharmaceuticals Oy: Faron commences a share offering -35,19% | 3,38 MEUR

2024-05-20 08:00:00 Faron Pharmaceuticals Oy: Initial positive data from Phase 2 of BEXMAB +6,00% | 2,22 MEUR

2024-05-17 17:00:00 Faron Pharmaceuticals Oy: Issuance of warrants

2024-05-16 16:01:08 Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 +4,17% | 0,77 MEUR

2024-05-16 08:05:00 Faron Pharmaceuticals Oy: Founders named European Inventor Award finalists +4,17% | 0,77 MEUR

2024-05-13 08:00:00 Faron Pharmaceuticals Oy: Replacement - Board Change +8,86% | 1,54 MEUR

2024-04-30 15:00:00 Faron Pharmaceuticals Oy: Update on financial status +3,57% | 0,19 MEUR

2024-04-30 14:00:00 Faron Pharmaceuticals Oy: Board Change +3,57% | 0,19 MEUR

2024-04-16 08:00:00 Faron Confirms Plans for the Coming Months Under New Leadership 0,00% | 0,22 MEUR

2024-04-16 08:00:00 Faron Pharmaceuticals Oy: Faron confirms plans under new leadership 0,00% | 0,22 MEUR

2024-04-15 08:00:00 Faron Pharmaceuticals Oy: Appointment of Chief Financial Officer -1,96% | 0,10 MEUR

2024-04-08 08:10:00 Faron Pharmaceuticals Oy: Approval of Warrant Terms and Conditions 0,00% | 0,12 MEUR

2024-04-08 08:05:00 Faron Pharmaceuticals Oy: Decisions of the Board of Directors 0,00% | 0,12 MEUR

2024-04-08 08:00:00 Faron Pharmaceuticals Oy: Appointment of Chief Executive Officer 0,00% | 0,12 MEUR

2024-04-05 13:00:00 Faron Pharmaceuticals Oy: Results of the Annual General Meeting -3,99% | 0,13 MEUR

2024-04-04 08:00:00 Faron Pharmaceuticals Oy: Announcement of Placing -8,00% | 5,62 MEUR

2024-03-28 08:00:00 Faron Pharmaceuticals Oy: Issue of Warrants to IPF Funding Update -1,79% | 0,17 MEUR

2024-03-26 11:00:00 Faron Pharmaceuticals Oy: Faron's Annual Report 2023 -1,72% | 0,25 MEUR

2024-03-18 14:00:00 Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML +25,00% | 0,70 MEUR

2024-03-18 08:00:00 Faron Pharmaceuticals Oy: Additional Positive Data from Phase 1 of BEXMAB +25,00% | 0,70 MEUR

2024-03-14 08:00:00 Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab -1,72% | 0,16 MEUR

2024-03-14 08:00:00 Faron Pharmaceuticals Oy: Faron to Host BEXMAB Webcast -1,72% | 0,16 MEUR

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2024-08-28	Kvartalsrapport 2024-Q2
2024-03-25	X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22	Årsstämma 2024
2024-03-14	Bokslutskommuniké 2023
2023-08-29	Kvartalsrapport 2023-Q2
2023-03-27	X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24	Årsstämma 2023
2023-03-03	Bokslutskommuniké 2022
2022-08-25	Kvartalsrapport 2022-Q2
2022-07-07	Extra Bolagsstämma 2022
2022-04-25	X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22	Årsstämma 2022
2022-03-25	Bokslutskommuniké 2021
2021-08-26	Kvartalsrapport 2021-Q2
2021-04-26	X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23	Årsstämma 2021
2021-03-25	Bokslutskommuniké 2020
2020-05-14	X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13	Årsstämma 2020
2020-03-20	Bokslutskommuniké 2019

Faron Pharmaceuticals

Kalender

Beskrivning

Faron Pharmaceuticals

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden